⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Phase IIGLP-1

Compound 61447

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061447
Risk Class
MODERATE
Last Audit
Feb 13, 2108

Research Abstract

GLP-1 candidate engineered for endocrine support initiatives with automated dossier coverage.

Compound 61447 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for endocrine support and performance longevity.

The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061447 with updates logged 2108-02-13.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Endocrine supportPerformance longevity

Nomenclature

CX-61447GLP-1 Program 61447

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061447
  2. [2] Operations Pulse • GLP-1 innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61447